Apogenix GmbH, of Heidelberg, Germany, reported final top-line results from a phase I trial of APG101, a fully human fusion protein, in low to intermediate-1 risk transfusion-dependent patients with myelodysplastic syndromes (MDS), showing the drug was well-tolerated and efficiently stimulated erythropoiesis.